InvestorsHub - NYSE, NASDAQ, AMEX, OTCBB, Pink Sheet Stock Message Boards, Stock Charts, Stock Quotes, Level II and Market News

Ticker	Name	Price	Change	Change %	Volume	Posts
RSLS	ReShape Lifesciences Inc	1.61	1.25	346.60%	255,080,531	2,796
BIAF	bioAffinity Technologies Inc	1.10	0.8400	323.08%	497,516,881	176
ICCT	iCoreConnect Inc	4.65	2.41	107.59%	209,697,268	3,653
GATE	Marblegate Acquisition Corporation	36.05	16.44	83.83%	159,592	2
QSG	QuantaSing Group Ltd	6.55	2.53	62.94%	10,274,530	76
NUTX	Nutex Health Inc	71.39	24.36	51.80%	315,260	7,593
TCRT	Alaunos Therapeutics Inc	2.18	0.7064	48.05%	5,410,726	1,236
CRWV	CoreWeave Inc	52.57	15.49	41.77%	38,422,840	8
SONM	Sonim Technologies Inc	2.95	0.8100	37.85%	1,489,613	164
MVST	Microvast Holdings Inc	1.55	0.3800	32.48%	41,926,716	166

Ticker	Board Name	Price	Change %	Posts (24h)
COOP	Mr Cooper Group Inc	125.08	0.00%	181
HMBL	HUMBL Inc	0.0003	0.00%	275
TWOH	Two Hands Corp	0.0014	-22.22%	263
RDAR	Raadr Inc	0.0007	+30.00%	134
AZRH	Azure Holding Group Corp	0.1599	0.00%	20
AMRN	Amarin Corp Plc	0.00	0.00%	23

	Board Name	Posts (24h)
	ORIONS Money Stocks	102
	Savvy Trades and Investments	52
	BBs Stock Haven	122
4	DD Support Board and Research Team	59
5	MOMOS BREAKOUT BOARD	92
6	Rigs Platinum Stock Alerts	48

Ticker	Name	Price	Change %	Market Cap	Volume ($)
BTC	Bitcoin	84,151.15	-1.20%	1,671.3B	3.9B	Message Board Quote News
ETH	Ethereum	1,856.39	-2.57%	224.2B	1.8B	Message Board Quote News
USDT	Tether USD	0.99995	0.00%	141.9B	285.9M	Message Board Quote News
XRP	Ripple	2.08	-2.80%	120.7B	961.8M	Message Board Quote News
BNB	Binance Coin	600.00	-1.86%	94.7B	419.2M	Message Board Quote News
SOL	Solana	124.20	-1.97%	60.7B	855.2M	Message Board Quote News
USDC	USD Coin	0.9999	-0.01%	56.1B	946.9M	Quote News
DOGE	Dogecoin	0.16843	-3.17%	25.0B	325.4M	Message Board Quote News
ADA	Cardano	0.6648	-1.83%	24.0B	159.8M	Message Board Quote News
TRX	TRON	0.236993	-0.35%	20.4B	99.1M	Message Board Quote News

Play Episode

7min

Proactive - Interviews for investors

Alpha HPA eyes global demand with stage 2 facility

Alpha HPA Ltd Managing Director Rob Williamson talked with Proactive at the AIM Small and Midcap conference about how the company is redefining aluminum purification through its novel solvent extraction technology. Alpha HPA is producing high-purity aluminum materials for advanced industries such as semiconductors, lithium-ion batteries, direct lithium extraction, and LED technologies. Williamson explained that while solvent extraction has been used in industries like copper and rare earths, Alpha HPA is the first to apply it to aluminum purification, allowing for significantly reduced energy input and improved sustainability. Williamson said, “We can produce our materials at a 70% lower carbon footprint compared to incumbent manufacturers.” This aligns with growing global demand for cleaner technologies and supports the energy transition. The company recently signed a letter of intent with a customer in the semiconductor market, targeting an alloy used in polishing silicon carbide wafers. The product is 50% more efficient than alternatives, and Williamson noted the Stage 2 facility, currently under construction, is expected to have 10,000 tonnes of annual capacity to meet rising demand. With a compelling cost structure and an average sales price of around USD 25 per kilo versus a material input cost of approximately USD 500 per tonne, Alpha HPA believes it is well-positioned for strong margins and market growth. #AlphaHPA #AluminumPurification #Semiconductors #GreenTechnology #EnergyTransition #HighPurityAluminum #CleanTech #BatteryMaterials #SustainableManufacturing #Stage2Facility

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

Wrkr CEO on super compliance growth strategy

Wrkr Limited CEO Trent Lund talked with Proactive at the AIM's Small and Midcap Conference about the company’s strategy to simplify compliance through a deeply integrated digital platform. The ASX-listed company, trading under the ticker WRK, connects users, employers, and superannuation funds to streamline data accuracy and reduce friction in onboarding processes. “We do all the hard work and the heavy lifting so the business and the employee don’t have to,” said Lund. He explained that Wrkr verifies user credentials and automates data flows, reducing error and increasing trust. The system connects to major superannuation funds and payroll systems, holding accurate user information even during job transitions. Lund detailed Wrkr’s monetisation model, which aims to earn approximately $7 per user through microservices, including license checks and transactions. Current pilots, including one with major fund REST, are transitioning to production. Each super fund implementation takes about nine months and represents between $7 million and $14 million in annual annuity revenue once fully operational. Looking ahead, 2025 will be focused on large-scale implementation, with 2026 anticipated to generate higher consumption-based revenues. In 2027, Wrkr expects a significant uplift with the introduction of payday super legislation. #WrkrLimited #TrentLund #ASXWRK #Superannuation #ComplianceTech #FintechAustralia #PayrollIntegration #InvestorUpdate #PaydaySuper #DigitalTransformation #DataVerification #WorkforceAutomation

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

U.S. Stocks Finish Volatile Session Mostly Higher

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

U.S. Stocks Finish Volatile Session Mostly Higher

Go Ad-Free